Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CEO and MD, and resignation of CEO and MD.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon's board on March 27, 2026 approved major leadership changes effective April 1, 2026, as part of integrating Biocon Biologics into the parent company. CEO & MD Siddharth Mittal and Interim CFO Mukesh Kamath will step down on March 31, 2026, both moving into other leadership roles within the Biocon Group. Shreehas Pradeep Tambe, currently CEO & MD of Biocon Biologics, has been appointed as the new CEO & MD of Biocon Limited for a five-year term, subject to shareholder approval. Kedar Narayan Upadhye, CFO of Biocon Biologics, will take over as Biocon's CFO. Additionally, Akhilesh Nand, Naveen Narayanan, and Mandar Ghatnekar (all from Biocon Biologics) have been elevated to senior positions at Biocon, while seven existing Senior Management Personnel, including the Chief Commercial Officer and Chief Scientific Officer, will cease in their roles. This follows the December 2025 announcement to create a unified global biopharmaceutical company.
This is a planned leadership transition tied to the Biocon-Biocon Biologics merger, not an unexpected exit. Since both new appointees continue in their Biocon Biologics roles, business continuity is largely preserved, though investors will watch closely for execution risks during the integration and the appointment of Shreehas Tambe as the first CEO of the combined entity.